Bluebird listing “releases the shackles” on RMX project

|

Published 11-APR-2016 11:42 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Red Mountain Mining (ASX:RMX) says the listing of Bluebird Merchant Ventures on the London Stock Exchange “releases the shackles” on its flagship Batangas gold project in the Philippines.

It told its shareholders today that Bluebird was on course for a listing on the LSE later today Australian time after it published an approved prospectus for a minimum 1.675 million pound ($A3.12 million) raising.

The listing of Bluebird is a vital cog in getting the Batangas gold project up and running, as the funds from the raising will go towards a definitive feasibility study for the project.

After the raising, Bluebird will pay RMX $1.6 million as part of a previous loan arrangement, while RMX has agreed to take a 4.7% stake in the newly listed LSE company.

Post payment of the loan, Bluebird is set to take a 25% stake in RMMS, the RMX subsidiary which holds the Batangas project.

This essentially values the project at $9 million, while RMX has a market cap of just over $2.6 million.

RMX managing director Jon Dugdale admitted that the listing process has been a while in the making, but now it was here, removed an overhang from the project.

“This releases the shackles on the project, and will allow the JV to get on with completing the DFS; a geotechnical and resource target drilling program, and permitting of the Batangas Gold Project development,” he told shareholders.

About Batangas

The funding is going towards a definitive feasibility study and drilling at the Batangas Gold Project in the Philippines.

Total mineral resources at Batangas sit at 2.97 million tonnes @ 2.4 grams per tonne gold for 227,000 on an indicated basis, and 3.22MT @ 2.1g/t for 218,000oz on an inferred basis.

RMX’s project in the Philippines

The Lobo area features 82,000 oz on an indicated and inferred basis – including the South West Breccia mine, which will be the first start-up mine at the project.

Free cash flow from production of the first 100,000oz is expected to be $45 million.

Capex at this stage is expected to be $15 million, a figure set out in a scoping study and feasibility update, but a definitive feasibility study would add more certainty around the numbers.

tags

GOLD


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X